BNP Paribas Financial Markets
INKT icon

BNP Paribas Financial Markets’s MiNK Therapeutics INKT Stock Holding History

BNP Paribas Financial Markets’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152 Sell
13
-3
-19% -$35 ﹤0.01% 5769
2026
Q1 		$168 Hold
16
– – ﹤0.01% 5645
2025
Q4 		$178 Hold
16
– – ﹤0.01% 5577
2025
Q3 		$224 Sell
16
-10
-38% -$160 ﹤0.01% 5382
2025
Q2 		$192 Buy
26
+3
+13% +$23 ﹤0.01% 5286
2025
Q1 		$199 Sell
23
-2
-8% -$18 ﹤0.01% 5212
2024
Q4 		$172 Buy
+25
New +$170 ﹤0.01% 5245

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

BNP Paribas Financial Markets's INKT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its MiNK Therapeutics (INKT) stake by 19% in Q2 2026, selling an estimated $35 and leaving 13 shares worth $152. The position accounts for ﹤0.01% of the portfolio, ranked #5769.

BNP Paribas Financial Markets first reported a position in INKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $224 in Q3 2025. 22 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • BNP Paribas Financial Markets held 13 shares of MiNK Therapeutics worth $152 as of Q2 2026.
  • BNP Paribas Financial Markets sold 3 MiNK Therapeutics shares in Q2 2026, an estimated $35.
  • MiNK Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5769 holding.
  • BNP Paribas Financial Markets first reported a position in MiNK Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's MiNK Therapeutics position peaked at $224 in Q3 2025.
  • 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.